{"id":"dwp14012-b-mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DWP14012 works by inhibiting the DPP-4 enzyme, which normally breaks down incretin hormones (GLP-1 and GIP). By preventing this degradation, the drug increases circulating levels of these hormones, which stimulate insulin secretion in response to meals and suppress glucagon secretion, thereby lowering blood glucose levels. This mechanism is particularly effective in postprandial (after-meal) glucose control.","oneSentence":"DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:27.106Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06508645","phase":"PHASE1","title":"Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-01-10","conditions":"Healthy Volunteers","enrollment":33},{"nctId":"NCT05812404","phase":"PHASE1","title":"Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-10-26","conditions":"Drug Drug Interaction","enrollment":36},{"nctId":"NCT03487562","phase":"PHASE1","title":"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2018-04-08","conditions":"Healthy","enrollment":48},{"nctId":"NCT03811080","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-02-07","conditions":"Non-Erosive Gastroesophageal Reflux Disease","enrollment":327}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DWP14012 B mg","genericName":"DWP14012 B mg","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}